

SPARC/Sec/SE/2022-23/078

November 22, 2022

National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/Madam,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions for the half year ended September 30, 2022

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Sun Pharma Advanced Research Company Limited

Dinesh Lahoti Company Secretary and Compliance Officer ICSI Membership No. A22471

Encl: As above

Sr. No.	Details of the party (listed entity /subsidiary) entering into the			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	to either result of the	onies are due party as a e transaction	inter-corporate disclosed only In case any fina make or give lo advances or in	estments period w ırred to sits,	Amount in Rs. Lakhs - applicable only in case the related party transaction relates to loans, made or given by the listed entity/subsidiary. These details need to be hen such transaction was undertaken Details of the loans, inter-corporate deposits, advances or investments						
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
1	Sun Pharma Advanced Research Company Limited	Dilip S. Shanghvi	Chairman and Non- executive Director	Any other transaction	Sitting Fees	-	Not Applicable	1.80	-		-		-	-	-	-	-	-	-
2	Sun Pharma Advanced Research Company Limited	Sudhir V. Valia	Non Executive Director	Any other transaction	Sitting Fees	-	Not Applicable	3.30	-		-		-		-	-	-	-	-
3	Sun Pharma Advanced Research Company Limited	Rajamannar Thennati	Non Executive Director	Any other transaction	Sitting Fees	-	Not Applicable	1.50	-		-		-	-	-	-	-	-	_
4	Sun Pharma Advanced Research Company Limited	Bhavna Doshi	Independent Director	Any other transaction	Sitting Fees	-	Not Applicable	3.30	-		-		-	-	-	-	-	-	-
5	Sun Pharma Advanced Research Company Limited	Ferzaan Engineer	Independent Director	Any other transaction	Sitting Fees	-	Not Applicable	2.70	-		-		-		-	-	-	-	-
6	Sun Pharma Advanced Research Company Limited	Robert Jay Spiegel	Independent Director	Any other transaction	Sitting Fees	-	Not Applicable	2.70	-		-		-	-	-	-	-	-	-
7	Sun Pharma Advanced Research Company Limited	Anilkumar Raghavan	Chief Executive Officer	Any other transaction	Remuneration	-	Not Applicable	285.15	-		-		-	-	-	-	-	-	-
8	Sun Pharma Advanced Research Company Limited	Chetan Rajapara	Chief Financial Officer	Any other transaction	Remuneration	-	Not Applicable	94.02											
9		Dinesh Lahoti	Company Secretary	Any other transaction	Remuneration	-	Not Applicable	12.54											
10	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of goods or services		2,826.44	Approved	2,826.44	-		-		-	-	-	-	-	-	-
11	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of fixed assets		25.70	Approved	25.39	-				-	-	-	-	-	-	

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	(listed party related party transaction transaction as approved by the audit committee					Remarks on approval by audit committee	Value of transaction during the reporting period	to either	nies are due party as a transaction	inter-corporate disclosed only In case any fina	e deposits, advar once, during the ancial indebtedn oans, inter-corpo	nces or inverse reporting	estments period w urred to	Amount in Rs. Lakhs are applicable only in case the related party transaction relates to loans, made or given by the listed entity/subsidiary. These details need to be when such transaction was undertaken Details of the loans, inter-corporate deposits, advances or linvestments Nature (loan/ Interest Tenure Secured/ Purpose for which					
	Name	Name	counterparty with the listed entity or its subsidiary						balance	balance	indebtedness (loan/ issuance of debt/ any other etc.)	other indebtedness	Cost	renure	advance/ inter- corporate deposit/ investment	Rate (%)	renure	Secured/ unsecured	the funds will be utilised by the ultimate recipient of funds (end- usage)	
12	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods or services		1000.00 *	Approved	338.60	-	-			-	-	-	-	-	-	-	
13	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of fixed assets		37.84	Approved	37.84	-	-	-		-	-	-	-	-	-	-	
14	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Rent Paid	726.82 #	Approved	104.62	-	-			-	-	-	-	-	-	-	
15	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods or services		34.08	Approved	34.08	-	-		-	-	-	-	-	-	-	-	
16	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Reimbursement of expenses paid	500.00 *	Approved	106.15	-	-			-	-	-	-	-	-	-	
17	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Reimbursement of expenses received	500.00 *	Approved	12.56	-	-	-	-	-	-	-	-	-	-	-	
18	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	transaction	Balance receivable / (Payable)	-	Not Applicable	-	1,389.45	1,920.63	-		-	-	-	-	-	-	-	
19	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of goods or services		2,612.26	Approved	2,612.26	-	-	-		-	-	-	-	-	-	-	
20	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods or services		500.00 *	Approved	1.17	-	-	-	•	-	-	-	-	-	-	-	

Sr. No.	No. party (listed entity /subsidiary) entering into the transaction			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	party approval by stion audit committee audit	y transaction during the	to either	nies are due party as a e transaction	inter-corporate disclosed only In case any fina	e deposits, advar once. during the ancial indebtedn oans, inter-corpo	estments period w urred to	Amount in Rs. Lakhs - applicable only in case the related party transaction relates to loans, made or given by the listed entity/subsidiary. These details need to be hen such transaction was undertaken Details of the loans, inter-corporate deposits, advances or investments Nature (loan/ Interest Tenure Secured/ Purpose for which					
	Name	Name	counterparty with the listed entity or its subsidiary						balance	balance	indebtedness (loan/ issuance of debt/ any other etc.)	other indebtedness	Cost	Tenure	advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
21	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Balance receivable / (Payable)	-	Not Applicable	-	1,372.78	1,499.39	-		-	-	-	-	-	-	-
22	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Medicare Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods or services		500.00 *	Approved	0.20	-	-	-		-	-	-	-	-	-	-
23	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Medicare Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Balance receivable / (Payable)	-	Not Applicable	-	,	-0.23	-		-	-	•	-	-	-	-
24	Sun Pharma Advanced Research Company Limited	PV Power Technologies Pvt. Ltd.	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of fixed assets		6.35	Approved	6.35	-	-	-		-	-	-	-	-	-	-
25	Sun Pharma Advanced Research Company Limited	PV Power Technologies Pvt. Ltd.	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Balance receivable / (Payable)	-	Not Applicable	-	-	-2.26	-		-	-	-	-	-	-	-
26	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of goods or services		0.83	Approved	0.83	-	-	-		-	-	-	-	-	-	-
27	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Reimbursement of expenses paid	500.00 *	Approved	333.17	-	-	-		-	-	-	-	-	-	-
28	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods or services		3,818.36	Approved	3,818.36	-	-	-		-	-	-	-	-	-	-
29	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods or services		500.00 *	Approved	0.71											

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction Name	entity (listed entity transaction transaction the ransaction transaction to the ransaction transaction					Remarks on approval by audit committee	proval by audit transaction during the	to either	nies are due party as a e transaction	inter-corporate disclosed only In case any fina	e deposits, advar once, during the ancial indebtedn oans, inter-corpo	nces or inverse reporting	estments period w urred to	Amount in Rs. Lakhs a - applicable only in case the related party transaction relates to loans, a made or given by the listed entity/subsidiary. These details need to be then such transaction was undertaken Details of the loans, inter-corporate deposits, advances or investments Nature (loan/ Interest Tenure Secured/ Purpose for which					
			counterparty with the listed entity or its subsidiary						balance	balance	indebtedness (loan/ issuance of debt/ any other etc.)	other indebtedness	Cost	renure	advance/ inter- corporate deposit/ investment	Rate (%)	renure	unsecured	the funds will be utilised by the ultimate recipient of funds (end- usage)	
30	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Balance receivable / (Payable)	-	Not Applicable	-	-1,681.54	-5,643.78	-		-	-	-	-	-	-	-	
31	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Europe BV	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods or services		3.19	Approved	3.19	-	-	-		-	-	-	-	-	-	-	
32	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Europe BV	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Reimbursement of expenses paid	500.00 *	Approved	2.97	-	-	-		-	-	•	-	-	-	-	
33	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Europe BV	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Balance receivable / (Payable)	-	Not Applicable	-	-16.97	-22.19	-		-	-	-	-	-	-	-	
34	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of goods or services		15.74	Approved	15.74	-	-	-		-	-	-	-	-	-	-	
35	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Balance receivable / (Payable)	-	Not Applicable	-	11.38	3.97	-	-	-	-	-	-	-	-	-	
36	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries U.S.A. Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Rent Paid	783.31 #@	Approved	50.17	-	-	-		-	-	-	-	-	-	-	
37	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries U.S.A. Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Balance receivable / (Payable)	-	Not Applicable	-	-	-50.17	-		-	-	-	-	-	-	-	
38	Sun Pharma Advanced Research Company Limited	Spiegel Consulting Llc.	Enterprises under significant influence/are controlled by Key Management Personnel	Any other transaction	Professional Fee Paid	264.39 #@	Approved	20.34	-	-	-		-	-	-	-	-	-		

Disclosure on Related Party Transaction under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2022

Amount in Rs. Lakhs

_																			Amount in Rs. Lakns	
S	 Details of the 									nies are due	Additional disc	losure of related	l party tra	nsactions	- applicable on	ly in case t	he related	party transact	ion relates to loans,	
N	o. party (listed		transaction	to either party as a inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These de									se details need to be							
	entity	transaction transaction transaction audit d							result of the transaction disclosed only once, during the reporting period when such transaction was undertaken									1		
	/subsidiary)	ry) as approved committee ry									In case any fina	ancial indebtedn	ess is inc	urred to	Details of the lo	ans, inter-	corporate of	deposits, adva	nces or	
	entering into					by the audit		period			make or give lo	oans, inter-corpo	rate depo	sits,	investments					
	the					committee		-			advances or investments									
	transaction																			
	Name	Name	Relationship of the						Opening	Closing	Nature of	Details of	Cost	Tenure	Nature (loan/	Interest	Tenure	Secured/	Purpose for which	
			counterparty with						balance	balance	indebtedness	other			advance/ inter-	Rate (%)		unsecured	the funds will be	
			the listed entity or its								(loan/	indebtedness			corporate				utilised by the	
			subsidiary								issuance of				deposit/				ultimate recipient	
											debt/ any				investment				of funds (end-	
											other etc.)								usage)	
3	9 Sun Pharma	Spiegel		Any other	Balance	-	Not	-	-18.95	-20.34										
	Advanced	Consulting Llc.	significant	transaction	receivable /		Applicable													
	Research		influence/are		(Payable)															
	Company		controlled by Key																	
	Limited		Management																	
			Personnel																	
	Total value of	f transactions dur	ing the reporting period	10,758.16																

Note

Values mentioned under the column "Value of the related party transactions as approved by the Audit Committee" are for FY23 except for multi year related party transactions, which are tagged seperately

- # Represent aggregate value of multi year related party transaction
- @ Approval granted by the audit committee in foreign currency are disclosed in INR, basis the closing exchange rate as on September 30, 2022
- * These transactions are also within the limits of overall aggregate omnibus limit granted by the Audit Committee